2024
Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink
Denoble A, Vazquez-Benitez G, Sheth S, Ackerman-Banks C, DeSilva M, Zhu J, Daley M, Getahun D, Klein N, Vesco K, Irving S, Nelson J, Williams J, Hambidge S, Donahue J, Weintraub E, Kharbanda E, Lipkind H. Coronavirus Disease 2019 (COVID-19) Vaccination and Stillbirth in the Vaccine Safety Datalink. Obstetrics And Gynecology 2024, 144: 215-222. PMID: 38843526, PMCID: PMC11250101, DOI: 10.1097/aog.0000000000005632.Peer-Reviewed Original ResearchVaccine Safety DatalinkAntepartum stillbirthVaccine Safety Datalink sitesLive birthsCOVID-19 vaccineVaccine dosePregnancy start dateRisk of severe morbidityRisk of stillbirthConditional logistic regressionCase-control studyVaccine manufacturersSingleton pregnanciesGestational ageFetal deathPostpartum visitMaternal ageIndex dateSevere morbidityDiagnostic codesPregnancyStillbirthPregnant peopleCOVID-19Logistic regression
2019
Spiking in the Second Stage: What are the Neonatal Implications? [19D]
Daifotis H, Smith M, Denoble A, Dotters-Katz S. Spiking in the Second Stage: What are the Neonatal Implications? [19D]. Obstetrics And Gynecology 2019, 133: 47s-46s. DOI: 10.1097/01.aog.0000558975.44644.1a.Peer-Reviewed Original ResearchSevere neonatal morbidityLength of stayNeonatal morbidityMaternal feverNICU admissionUntreated womenTerm singleton vaginal deliveriesInvasive respiratory supportSingleton vaginal deliveriesAntepartum complicationsAntibiotic receiptNeonatal implicationsPostnatal antibioticsACOG guidelinesRespiratory supportRetrospective cohortInfectious signsPrimary outcomeSevere morbidityVaginal deliveryMaternal treatmentUntreated groupMorbidityIRB approvalNeonates